Protein Inhibitors - ABT-263 (CAS: 923564-51-6)

Location：Home > Biochemicals > Protein Inhibitors

ABT-263 (CAS: 923564-51-6)

Catalog #：EBC51003

Datasheet

ABT-263 (CAS: 923564-51-6)

SKU-Pack Size	Availability	Size	Price
EBC51003-1ML	In Stock	1mL(10mM in DMSO)	€128.70
EBC51003-5MG	In Stock	5mg	€76.70
EBC51003-10MG	In Stock	10mg	€115.70
EBC51003-50MG	In Stock	50mg	€258.70
EBC51003-100MG	In Stock	100mg	€453.70

If you want to get a larger packsize, Please contact your local distributor or
email us atinfo@ebiocell.com

Please Select The Country You Are In To Find Your Local Distributor.

	Betaclonal	Phone：+34 (0)91 471 6763
	29/1 Lomonosovsky Pr,	E-mail：tech@betaclonal.com
Spain	Madrid, Spain	Web：www.betaclonal.com

Product Information

Synonym(s)

Navitoclax, ABT263, ABT 263

Chemical Name

(R)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide

Application

ABT-263 is a bcl-2 family protein inhibitor

CAS Number

923564-51-6

Purity

≥99%

Molecular Weight

974.61

Molecular Formula

C₄₇H₅₅ClF₃N₅O₆S₃

SMILES

CC1(C)CCC(=C(CN2CCN(CC2)C2=CC=C(C=C2)C(=O)NS(=O)(=O)C2=CC(=C(N[C@H](CCN3CCOCC3)CSC3=CC=CC=C3)C=C2)S(=O)(=O)C(F)(F)F)C1)C1=CC=C(Cl)C=C1

Target & IC50

EOL1: IC50 = 6.69 nM
NKM-1: IC50 = 16.99 nM
ML-2: IC50 = 19.83 nM
BV-173: IC50 = 23.14 nM

Solubility

DMSO: 100 mg/mL (102.6 mM)

Preparing Stock Solutions

ConcentrationSolventMass	1 mg	5 mg	10 mg
1 mM	1.0261 ml	5.1303 ml	10.2605 ml
5 mM	0.2052 ml	1.0261 ml	2.0521 ml
10 mM	0.1026 ml	0.5130 ml	1.0261 ml
50 mM	0.0205 ml	0.1026 ml	0.2052 ml

Shipping

Gel Pack

Storage

Store at -20°C

Research Use

For Research Use Only. Not Intended for Diagnostic Or Therapeutic Use.

Product Description

ABT-263 is a novel inhibitor of antiapoptotic BCL-2 proteins and a new promising anticancer drug candidate.
ABT-263 is active against approximately one-half of the cell lines of the PPTP in vitro panel. The median IC50 for all of the lines in the panel is 1.91 µM. Navitoclax in combination with chemotherapy agents leads most ovarian cancer cell lines a synergistic response, and enhances the caspase activation in both SK-OV-3 and IGROV-1 cell lines.

Specific Protocols

>>	Western Blotting Protocol	>>	Immunoprecipitation Protocol
>>	Immunohistochemistry Protocol	>>	Immunofluorescence Protocol
>>	Immunocytochemistry Protocol	>>	Flow Cytometry Protocol
>>	ChIP Protocol	>>	ELISA Protocol
>>	HPLC Protocol	>>	PCR Protocol